Aicardi-Goutières syndrome is a genetically determined infantile encephalopathy, manifesting as progressive microcephaly, psychomotor retardation, and in $25% of patients, death in early childhood. Aicardi-Goutières syndrome is caused by mutations in any of the genes encoding TREX1, RNASEH2-A, -B, -C and SAMHD1, with protein dysfunction hypothesized to result in the accumulation of nucleic acids within the cell, thus triggering an autoinflammatory response with increased interferon-a production. Astrocytes have been identified as a major source of interferon-a production in the brains of patients with Aicardi-Goutières syndrome. Here, we study the effect of interferon-a treatment on astrocytes derived from immortalized human neural stem cells. Chronic interferon-a treatment promoted astrocyte activation and a reduction in cell proliferation. Moreover, chronic exposure resulted in an alteration of genes and proteins involved in the stability of white matter (ATF4, eIF2Ba, cathepsin D, cystatin F), an increase of antigen-presenting genes (human leukocyte antigen class I) and downregulation of pro-angiogenic factors and other cytokines (vascular endothelial growth factor and IL-1). Interestingly, withdrawal of interferon-a for 7 days barely reversed these cellular alterations, demonstrating that the interferon-a mediated effects persist over time. We confirmed our in vitro findings using brain samples from patients with Aicardi-Goutières syndrome. Our results support the idea of interferon-a as a key factor in the pathogenesis of Aicardi-Goutières syndrome relating to the observed leukodystrophy and microangiopathy. Because of the sustained interferon-a effect, even after withdrawal, therapeutic targets for Aicardi-Goutières syndrome, and other interferon-a-mediated encephalopathies, may include downstream interferon-a signalling cascade effectors rather than interferon-a alone.
Introduction
Aicardi-Goutiè res syndrome is a rare genetic disease in which severe neurological dysfunction usually becomes apparent in infancy. Affected children most typically present with irritability, inconsolable crying, dystonia, hypotonia and seizures in early life, leading to progressive microcephaly, with severe developmental delay and death in $25% of cases (Barth et al., 1999; Crow and Rehwinkel, 2009 ). Aicardi-Goutiè res syndrome is characterized by cerebral atrophy, white matter damage, brain calcifications and, one of the hallmarks of the disease, the presence of high levels of interferon-alpha (IFN-) in the CSF and serum (Lebon et al., 1988) .
Because of the clinical and biochemical features of the disease, Aicardi-Goutiè res syndrome is easily confused with a congenital infection (e.g. as a result of toxoplasmosis, HIV, rubella virus, cytomegalovirus and/or herpes simplex virus); therefore, the diagnosis of Aicardi-Goutiè res syndrome is usually only considered after exclusion of an infectious aetiology (Sanchis et al., 2005) . The observation of chilblains (skin ulcerations), hepatosplenomegaly, thrombocytopaenia and autoantibodies suggest an immune pathogenic mechanism (Rice et al., 2007) . Interestingly, IFNlevels are higher in CSF than in the serum of these patients, indicative of an intrathecal production (Lebon et al., 1988) . Indeed, astrocytes have been identified to be a major source of IFN-, among other cytokines, such as CXCL10, in the brain of patients with Aicardi-Goutiè res syndrome (van Heteren et al., 2008) .
Neuropathological data have also suggested that AicardiGoutiè res syndrome may represent a primary microangiopathy (Barth et al., 1999) , as peri-and intravascular calcium/mineral deposits and cortical microinfarctions are occasionally found, a hypothesis supported by the pattern of changes seen on brain imaging, and the frequently reported finding of a vasculitis on biopsy of the chilblain lesions (Ramesh et al., 2010) . These observations suggest that an inflammatory disturbance of vascular homeostasis may be important in the pathogenesis of Aicardi-Goutiè res syndrome.
Aicardi-Goutiè res syndrome is a genetically heterogeneous disorder. To date, mutations have been identified in five genes accounting for 90% of Aicardi-Goutiè res syndrome cases. These genes encode the DNA exonuclease 1 (TREX1; Crow et al., 2006a) , the three subunits of the endoribonuclease H2 complex (RNASEH2B, RNASEH2C and RNASEH2A; Crow et al., 2006b) , and the deoxynucleoside triphosphate triphosphohydrolase SAMHD1 (Rice et al., 2009; Goldstone et al., 2011; Powell et al., 2011) . All of these proteins are important in nucleic acid metabolism, and it is now believed that the innate immune response might occur as a result of nucleic acid accumulation in cells (Yang et al., 2007) , thus mimicking a viral infection. Recently, data have revealed that SAMHD1 might act as a restriction factor for HIV infection (Berger et al., 2011; Hrecka et al., 2011; Laguette et al., 2011) , and that TREX1 (Yan et al., 2010) and RNASEH2A (Genovesio et al., 2011) also have a role in the metabolism of HIV.
Trex1 null mice exhibit a reduced survival and develop inflammatory myocarditis. A cerebral phenotype has not been observed in these animals (Morita et al., 2004; Gall et al., 2012) . The cardiac inflammation is dependent on IFN-receptor 1 (IFNR1), interferon responsive factor 3 (IRF3) and the ability to generate autoantibodies by mature B cells. Abrogation of any of these three interferon-dependent signalling cascades is sufficient to circumvent lethality in mice (Stetson et al., 2008) . Furthermore, in these animals, it has recently been demonstrated that the accumulation of Trex1 DNA substrates leads to the activation of the interferon-stimulatory DNA response through the adaptor protein STING, and that type I interferons drive the autoreactive response causing the myocarditis (Gall et al., 2012) . Ablation of Rnaseh2b in mice leads to early embryonic lethality because of elevated DNA damage and p53-dependent growth arrest (Reijns et al., 2012) .
Although not a genetic model for Aicardi-Goutiè res syndrome, transgenic mice overexpressing IFN-under control of the astrocytic glial fibrillary acidic protein (GFAP) promoter (so-called GIFN mice), develop a progressive inflammatory encephalopathy, with calcium deposits, gliosis and neurodegeneration (Akwa et al., 1998; Campbell et al., 1999) . These latter findings are remarkably similar to those observed in patients with Aicardi-Goutiè res syndrome, and thus implicate a pathogenic role for IFN-in the cerebral pathology of Aicardi-Goutiè res syndrome.
An additional indication of a detrimental role of IFN-in Aicardi-Goutiè res syndrome was provided by microarray studies on lymphocytes from CSF samples of patients. These studies showed an upregulation of interferon-related genes together with a downregulation of angiogenesis-related transcripts (Izzotti et al., 2009) . Moreover, it has been demonstrated that mutations in TREX1 potentiate the anticancer properties of T lymphocytes to inhibit growth of neuroblastoma cells and related angiogenesis, and that these effects were enhanced in the presence of IFN- (Pulliero et al., 2012) .
Here, we establish an in vitro model of Aicardi-Goutiè res syndrome using human neural stem cell-derived astrocytes chronically treated with IFN-. Despite the emerging evidence linking IFNto autoimmunity, little is known about the specific mechanisms that lead to disease in human brain cells. We show that chronic IFN-exposure reduces cell proliferation while promoting the activation and reactivity of astrocytes. Although a defect in endogenous RNA/DNA metabolism in Aicardi-Goutiè res syndrome may be central to disease pathogenesis (Stetson et al., 2008; Gall et al., 2012) , we demonstrate that IFN-alone may induce changes in the expression of genes and proteins related to white matter stability and vascular growth and development, in the absence of any mutation. Finally, we confirm our in vitro results in astrocyte cultures using human post-mortem brain specimens from patients with Aicardi-Goutiè res syndrome. Together, these findings provide support for the hypothesis that blocking interferon signalling might be beneficial in Aicardi-Goutiè res syndrome and other IFN-mediated encephalopathies.
foetus, were cultured and propagated as previously described (De Filippis et al., 2007) . Briefly, neurospheres were cultured in Euromed-N medium (Euroclone) supplemented with 25 mg/ml insulin, 100 mg/ml transferrin, 6.3 ng/ml progesterone, 9.6 mg/ml putrescine, 520 ng/ml sodium selenite (N2 supplement, all from Sigma), 20 ng/ml epidermal growth factor and 10 ng/ml of fibroblast growth factor 2 (both from Tebu-Bio) in uncoated dishes.
To differentiate immortalized human neural stem cell into astrocytes, individual spheres were mechanically dissociated and transferred at a density of 20 000 cells/ml onto laminin-coated plates. Cells were grown for 21 days in vitro in normal supplemented-Euromed-N medium in the presence of 2% foetal calf serum without growth factors. During this period, cell medium was refreshed twice a week in the presence/absence of the afterwards indicated concentrations of human pegylated interferon alpha-2a (Pegasys Õ , Roche).
Post-mortem human brain material
Tissue from Aicardi-Goutiè res syndrome and healthy control subjects was obtained from The Netherlands Brain Bank (Amsterdam, The Netherlands), the Department of Neuropathology, Academic Medical0 Centre (Amsterdam, The Netherlands) and from the Department of Paediatrics at the Rikshospitalet (Oslo, Norway). The brain donors gave informed consent for using the tissue and for accessing the extensive neuropathological and clinical information for scientiEc research, in compliance with ethical and legal guidelines. Clinicopathological information of all donors can be found in Table 1 .
Real-time quantitative polymerase chain reaction assay RNA from cell pellets was isolated using TRIzol Õ (Invitrogen Life
Technologies Europe) and precipitated overnight in isopropanol. Total RNA (500 ng) was DNase I treated and was used as a template to generate complementary DNA following the manufacturer's instructions (QuantiTect Reverse Transcription Kit, Qiagen) with a blend of oligo-dT and random hexamer primers. The reverse transcriptase and real-time quantitative PCR reactions were performed as previously described (Kamphuis et al., 2012) . Briefly, the reverse transcriptase reaction was incubated at 42 C for 30 min. 
Immunohistochemistry
We performed immunohistochemistry on 6-mm thick frontal sections of paraffin-embedded brain material from two patients with AicardiGoutiè res syndrome and two control subjects (Table 1) , as described previously (van den Berge et al., 2010) . In brief, sections were rehydrated and rinsed with Tris-buffered saline. Sections were pre-incubated with horse serum-containing buffer and were incubated overnight in the primary antibody solution (Supplementary Table 3) . After peroxidase blocking, sections were subsequently incubated with a biotinylated secondary antibody, avidin-biotin complex (Vector Laboratories) and diaminobenzidine tetrahydrochloride (Vector Laboratories). Finally, sections were counterstained with haematoxylin, dehydrated and mounted for microscope analysis.
Calcium deposits staining
Cells were fixed in 4% ice-cold paraformaldehyde for 15 min at room temperature and subsequently stained with modified alizarin red staining (Kawazoe et al., 2008) or von Kossa staining (Bonewald et al., 2003) by standard procedures.
Western blot
Protein was isolated from cells by homogenization with lysis buffer (0.1 M NaCl, 0.01 M Tris-HCl pH 7.6, 1 mM EDTA pH 8.0) supplemented with protease inhibitors phenylmethylsulphonyl fluoride (100 mg/ml) and aprotinin (0.5 mg/ml) cocktail (Roche Diagnostics). Protein content was determined using the BCA protein assay kit (Thermo Scientific). The same amounts of protein were dissolved in 2Â loading buffer (2Â : 100 mM Tris, 4% SDS, 20% glycerol, 200 mM dithiothreitol, 0.006% bromophenol blue) and boiled for 
Flow cytometry
Pelleted cells were resuspended in 0.1 M of phosphate buffer containing 0.1% egg albumin. Cells were then incubated with a mouse anti-human HLA-ABC-PE antibody (BD Pharmingen TM ) for 30 min at 4 C in darkness.
Cells were washed and resuspended in 0.1 M of phosphate buffer containing 0.1% egg albumin, and fluorescence-activated cell sorting analysis was immediately performed using the BD FACSCanto TM II flow cytometer (BD Biosciences). Collected data were analysed using FlowJo Software version 7.6.3 (TreeStar).
Luminex
Briefly, 25 ml of supernatants was analysed using a custom Bio-Plex Pro TM human cytokine 27-plex panel antibody kit according to the manufacturer's protocol (BioRad). Plates were then read on a BioPlex Protein Array System (BioRad) using both supplied high and low calibration curves, according to the instructions of the manufacturer. This technique allowed us to study the following cytokines: IL-1b, IL-1r, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17A, basic FGF, G-CSF, GM-CSF, IFN-, IP-10, MCP-1 (MCAF), MIP-1, MIP-1b, PDGF-BB, CCL5, TNF-and VEGF (vascular endothelial growth factor). Data analysis was performed with Bio-Plex Manager software (BioRad).
Statistics
All experiments were performed at least three independent times unless otherwise specified. Graphs are presented as bar charts or box plots to give mean AE standard error of mean (SEM). The variable distribution was assessed by Kolmogorov-Smirnov test. When test distribution was normal, a Student t-test was used to determine mean differences between two groups. When distribution was not normal, a non-parametric Mann-Whitney test was used. Kruskal-Wallis test was used followed by Dunn's multiple comparison test to assess intergroup differences. A P-value of 50.05 was considered statistically significant at a 95% confidence level. Tests were performed as indicated using Prism 4.0 (GraphPad Software Inc).
Results
Immortalized human neural stem cells give rise to mature functional astrocytes in vitro
We dissociated neurospheres into single cell suspension and cultured them as indicated above for 21 days in vitro (Fig. 1A and B) .
After this period, we stained the cells for different cell markers to assess the purity of the cultures. Cells showed positive staining of the astrocyte marker GFAP (Fig. 1C ) and the glia-specific calcium-binding protein S100b (Fig. 1D ). Cells were slightly positive for bIII-tubulin (Fig. 1E ) and negative for mature neuronal marker NeuN (Fig. 1F ). Cells showed no staining for both oligodendrocytic CNPase (Fig. 1G ) and microglial CD11b (Fig. 1H ) markers. Cells were harvested, and lysates were analysed by western blot against different commonly used astrocyte markers, which showed that after 21 days in vitro, they were positive for pan-GFAP, S100b, glutamine synthetase and vimentin (Fig. 1I ).
The differences in GFAP and S100b pattern observed in the brain homogenate can be attributed to a different GFAP degradation and its different isoforms, and the increase of S100b that occurs in the aged and Alzheimer brain as previously described (DeArmond et al., 1983; Sheng et al., 1996; Hol et al., 2003) .
To assess the capacity of these astrocytes to react to an innate immune system stimulus, we treated the astrocytes for 48 h with 10 mg/ml of polyinosinic:polycytidylic acid. Gene expression analysis ( Fig. 1J ) clearly showed that polyinosinic:polycytidylic acid promoted a robust increase in the expression of different IFNsubtypes, representative of the different anti-viral activity categories (Moll et al., 2011) : low activity IFNA1 (P = 0.034), high activity IFNA2 (P = 0.0079) and intermediate activity IFNA4 (P = 0.034). The cytokine CXCL10 (P = 0.015) and the intermediate filament protein GFAP (P = 0.015), which is a marker for reactive gliosis, were also highly upregulated in treated cells compared with vehicle-treated control cells. Furthermore, we also analysed the release to the supernatant of cytokines in these cultures (Fig. 1K ). After polyinosinic:polycytidylic acid treatment, the astrocytes produced and released significant amounts of IL-6 (P = 0.021), IL-8 (P = 0.046), CXCL10 (P = 0.015), CCL5 (P = 0.028) and TNF-(P = 0.047).
Chronic IFN-a exposure reduces astrocyte proliferation while promoting reactive gliosis In Trex1-deficient mice IRF3-dependent type I interferon response is identifiable in utero and is reliably detectable in specific tissues within a day after birth (Gall et al., 2012) . In humans, the moment at which the interferon response is initiated remains unknown and may vary according to genotype and/or stochastic factors.
To assess whether IFN-has an effect in the early stages of neurodevelopment, we plated the single cell dissociatedneurospheres in complete medium containing increasing doses of IFN-. After 5 days in vitro, the number of newly formed neurospheres and their diameters were measured ( Fig. 2A) . Analysis of these data revealed no differences when compared with vehicle-treated control cells ( Fig. 2B and C) .
We next examined the effect of IFN-in the differentiation and growth of the neural stem cells into astrocytes. Cultures were treated during the 21 days in vitro of differentiation process with increasing doses of IFN-. After this period, cells were stained against proliferation marker Ki67 (Fig. 2D) . We found that cells treated with 20 pg/ml of IFN-already showed a reduction in the proliferation (percentage of Ki67-positive nuclei: 53.35% AE 5.38, P = 0.039, Fig. 2E ) compared with vehicle-treated control cells (69.89% AE 1.16). This reduction in the proliferation was even more pronounced when cells were treated with 200 pg/ml of IFN-(45.68% AE 1.58, P = 0.0002).
We observed that after IFN-treatment, immortalized human neural stem cells gave rise to mature astrocytes, without affecting their viability ( Supplementary Fig. 1 ), but those astrocytes underwent morphological changes compared with control cells.
Treated cells presented a more pronounced star-like cellular shape and a more bundled intermediate filament network (Fig. 2F) , which is a typical sign of astrogliosis (Stichel and Mü ller, 1998; Sofroniew and Vinters, 2010) . We, therefore, studied the expression of intermediate filaments by real-time quantitative PCR (Fig. 2G) . We demonstrated that IFN--treated cells indeed showed increased expression of GFAP (P 5 0.05), S100B (P 5 0.05) and vimentin (VIM, P 5 0.05). To corroborate these results, we performed western blot analysis to confirm the increase in protein Astrocytes chronically exposed to IFN-a exhibit an alteration of expression of genes and proteins related to white matter stability and antigen presentation
We investigated whether IFN-alters the expression of ATF4 and EIF2B1, both crucial factors for another leukodystrophy known as vanishing white matter disease (Bugiani et al., 2010) . In lymphocytes of patients with Aicardi-Goutiè res syndrome, an alteration in the expression of genes, such as the myelin-degrading protease cathepsin D (CTSD) and its inhibitor cystatin F (CST7) (Izzotti et al., 2009) , has been shown previously. It is assumed that the cathepsin/cystatin ratio is crucial for the induction of white matter damage. Although suggested, a direct relationship between IFNlevels and changes in gene expression has not been proven. Moreover, these changes have been described in lymphocytes, whereas a pathological role is more likely relevant to brain cells (Bugiani et al., 2010) .
To confirm these assumptions, we examined the effect of acute and chronic IFN-exposure to our astrocytes in vitro. When fully differentiated mature astrocytes were treated with IFN-acutely for 24 h, no significant differences in gene expression variation were detected (Fig. 3A) . However, we observed an induction in expression of the antigen presenting HLA-C gene. On the other hand, when astrocytes were differentiated in the continuous presence of IFN-, we found a significant reduction of ATF4 (P 5 0.05, Fig. 3B ), EIF2B1 (P 5 0.05) and CTSD (P 5 0.05). Although not significant, we also observed an increase in CST7 and a marked induction of the HLA-C gene (P 5 0.001). Consistent with these data, western blot analysis confirmed a reduction of ATF4 and CTSD levels, together with an increase in CST7 (Fig. 3C) . Furthermore, analysis of the cells by flow cytometry (Fig. 3D ) revealed a significant increase in overall surface presentation of human leukocyte antigen class I compared with vehicle-treated control cells (P 5 0.01, Fig. 3E ).
As in humans, the mutations in Aicardi-Goutiè res syndromerelated genes drive a type I interferon response, we also explore the possibility of a cross-talk between these genes and IFN- (Fig. 3F) . We analysed the expression of the five Aicardi-Goutiè res syndrome causative genes, but neither acute nor chronic IFN-treatment produced an alteration in TREX1 or RNASEH2 A/B/C expression. In contrast, SAMHD1 expression was enhanced after an acute exposure of IFN-(P 5 0.05), although this effect disappeared after chronic treatment.
Astrocytes reduce the production and release of angiogenic factors, but do not produce calcium deposits after chronic IFN-a exposure in vitro Neuropathological data have suggested that Aicardi-Goutiè res syndrome may represent a primary angiopathy (Barth et al., 1999) affecting not only small blood vessels (Richards et al., 2007) but also, at least in the case of SAMHD1-related disease, large arteries (Ramesh et al., 2010) . In our autopsy specimens from patients with Aicardi-Goutiè res syndrome, we also observed a proliferation of small vessels and arterioles and many foci of juxtaposed blood vessels (Fig. 4A) . We, therefore, explored whether IFN-directly influences the vascular homeostasis by studying the production of angiogenic/vascular factors by astrocytes in vitro.
The expression levels of pro-angiogenic factors IL-1 and VEGF in chronically IFN--treated astrocytes were dramatically reduced (Fig.  4B) . Transcript levels of VEGFB (P 5 0.05), IL1A (P 5 0.01) and IL1B (P 5 0.01) were significantly lower than vehicle-treated control cells. Transcript levels of VEGFA were also lower in treated astrocytes, but those differences were not significant. Moreover, western blots clearly demonstrated an intracellular reduction of VEGF-A, VEGF-B and IL-1b, especially after high dose IFN-treatment (Fig. 4C) . We subsequently measured the levels of cytokines in the supernatants. There was a trend towards a reduction in the level of pro-angiogenic cytokines VEGF-A (P = 0.09) and IL-1b (P = 0.22) in supernatants of astrocytes treated chronically with IFN- (Fig. 4D) . The levels of TNF-(P = 0.035) were significantly reduced. The rest of the analysed cytokines did not show any significant changes ( Supplementary Fig. 2 ).
In Aicardi-Goutiè res syndrome brain, lamellar calcium deposits are widespread in the cerebral and cerebellar white matter as well as around small blood vessels (Barth et al., 1999 ). Thus, we tested whether astrocytes were responsible for producing these calcium inclusions after constant IFN-exposure. We assessed the expression of genes related to intracranial calcifications, such as SLC20A2 (Wang et al., 2012) , COL4A1 (Livingston et al., 2011) and osteopontin (now known as SSP1) (Shin et al., 2012) . We could not find any significant differences in SLC20A2 and COL4A1 expression between cell cultures treated with IFN-or vehicle, and we were not able to detect any osteopontin transcripts in our astrocyte cultures ( Fig. 4E ; data not shown). We also stained the astrocyte cultures for calcium deposits by using alizarin red and von Kossa techniques (Fig. 4F) . The dyed wells revealed no positive staining compared with the CaCO 3 control wells. These results indicate that astrocytes are not responsible for producing the extracellular calcium inclusions after IFN-treatment in vitro.
CST7 is overexpressed and VEGF and IL-1 are downregulated in Aicardi-Goutiè res syndrome brains
To study whether the observed in vitro changes also occur within the brain of patients with Aicardi-Goutiè res syndrome, we performed immunohistochemical stainings on autopsy specimens from two patients with Aicardi-Goutiè res syndrome (Barth et al., 1999; Rasmussen et al., 2005; van Heteren et al., 2008) .
As previously described, Aicardi-Goutiè res syndrome samples showed an intense immunoreactivity against IFN-in cells identified as astrocytes (van Heteren et al., 2008) , in both the grey matter (Fig.  5A ) and even more so in the white matter (Fig. 5B ) compared with control white matter (Fig. 5C ). Moreover, in some areas, some blood vessels also appeared positive for IFN- (Fig. 5A) . We performed similar staining against CST7. Those stainings revealed a modest increase for CST7 in cortical neurons in patients with Aicardi-Goutiè res syndrome (Fig. 5E ) compared with control subjects (Fig. 5D ). The increase, however, was more pronounced in the white matter of patients with Aicardi-Goutiè res syndrome ( Fig. 5G and H) compared with healthy control white matter (Fig. 5F ). Double staining with GFAP confirmed astrocytes as the major source of CST7 (Fig. 5I) , and these cells typically appeared to surround blood vessels.
We also evaluated the expression of pro-angiogenic factors IL-1b and VEGF-B. Immunostaining of IL-1b was strong in both grey matter and white matter of control specimens (Fig. 5J and L) compared with an almost absent reactivity in Aicardi-Goutiè res syndrome specimens (Fig. 5K and M) . For VEGF-B, a strong expression was found confined to the white matter of control cases ( Fig. 5O and Q) , and almost no expression was observed in the white matter of Aicardi-Goutiè res syndrome cases (Fig. 5R) . On the other hand, some neurons in patients with Aicardi-Goutiè res syndrome showed stronger staining for VEGF-B than in control brains (Fig. 5P) . Taken together, these results validated our previous in vitro findings. Continuous IFN-a exposure changes are persistent, and astrocytes do not recover pretreatment status after 7 days withdrawal of IFN-a Given the effects of IFN-in the astrocyte cultures, and considering that an anti-interferon might potentially be beneficial for patients with Aicardi-Goutiè res syndrome, we decided to explore the effect of withdrawing the IFN-in our in vitro system. For this purpose, cells were grown in the presence of IFN-as previously described but, after 14 days in vitro, IFNtreatment was discontinued, and cells were washed and cultured for an additional 7 days (Fig. 6A) . After this period, we measured the messenger RNA expression of the genes that we have previously shown to be affected by IFN-continuous exposure. We found that analysed transcripts did not recover pre-treatment levels after 7 days of IFN-withdrawal (Fig. 6B) . Only HLA-C showed a significantly reduced expression after IFN-removal (P 5 0.001). We also measured cytokines in the supernatant from these cell cultures. IFN-withdrawal did not significantly produce a recovery of the cytokine levels of IL-1b, VEGF or TNF-, although a trend was observed in the latter two (Fig. 6C) . The levels of IL-6 (P = 0.021) and G-CSF (P = 0.0092) did, however, show a recovery after IFN-treatment discontinuation. The rest of the analysed cytokines did not show any significant changes ( Supplementary  Fig. 3 ). Altogether, these results demonstrate that the changes that follow IFN-chronic treatment are persistent over time.
Discussion
IFN-is associated with a number of diseases affecting the CNS including, among others, Aicardi-Goutiè res syndrome, systemic lupus erythematosus, TORCH congenital infections and HIV-associated dementia. With the in vitro model presented here, we confirm that IFN-, even in the absence of an underlying Aicardi-Goutiè res syndrome mutation, can induce many of the characteristic changes that occur in the context of (14d) and IFN-withdrawal for 7 days. Results are expressed in pg/ml (mean AE SEM, n = 6). Statistically significant differences are expressed as *P 5 0.05, **P 5 0.01 and ***P 5 0.001.
Aicardi-Goutiè res syndrome-related pathophysiology. We also confirm that astrocytes constitute a major source of CXCL10 in CNS tissue when activated, as previously described in IFN--overexpressing (GIFN) mice (Akwa et al., 1998; Campbell et al., 1999) and in Aicardi-Goutiè res syndrome brain samples (van Heteren et al., 2008) .
One of the questions relating to Aicardi-Goutiè res syndrome pathogenesis is the stage at which the disease process begins. In Trex1-deficient mice, the interferon response develops in utero and precedes lymphocyte-dependent inflammation and autoimmune tissue damage (Gall et al., 2012) . In humans, it remains unknown when exactly the interferon-stimulatory DNA response becomes activated. Depending on the genotype, patients might present with signs and symptoms after several months of normal development (Aicardi and Goutiè res, 1984; McEntagart et al., 1998; Rice et al., 2007) . Our observations confirm that exposure of neural stem cells to IFN-neither affects their growth nor their differentiation into mature astrocytes, thus supporting the idea that brain development during the embryonic stage may well be normal, at least for patients with a milder phenotype.
Moreover, our results also demonstrate that astrocytes on chronic exposure to IFN-, reduced their proliferation and became reactive by increasing astrocyte-specific proteins and by changing their morphology with extended membrane processes. Similar findings were observed in murine astrocytes treated with IFN-/b together, with a disorganization of intermediate GFAP filaments (Tedeschi et al., 1986) .
Our data may also provide a link between IFN-and the white matter pathology observed in post-mortem Aicardi-Goutiè res syndrome brains. In the histology of these brains, subcortical white matter showed dense anisomorphic fibrous astrocytosis and in the cerebellum, excessive Bergmann glial fibres were also found, in addition to demyelination (Barth et al., 1999) .
Abnormal white matter on brain imaging is observed in almost all patients with Aicardi-Goutiè res syndrome during the first year of life (Rice et al., 2007) . Additionally, in GIFN mice, a degeneration of myelinated axons in the cerebellar white matter is seen (Campbell et al., 1999) . Although the exact mechanism by which IFN-might lead to a disturbance of myelin is unknown, a microarray study analysing Aicardi-Goutiè res syndrome lymphocytes from CSF showed an upregulation in the proteolytic enzyme CTSD and its inhibitor CST7 (Izzotti et al., 2008 (Izzotti et al., , 2009 ). This study also showed an age-dependent increase in the expression of DNAJ (heat shock protein 40), an important component of a negative feedback loop involved in inhibiting IFN-signalling (van Huizen et al., 2003; Izzotti et al., 2009) . Our data confirm that chronic IFN-produced a downregulation of CTSD together with an upregulation of CST7 as a counteracting mechanism to attenuate IFN-signalling, as was previously suggested (Izzotti et al., 2009; Pulliero et al., 2011) . The fact that we found a downregulation of CTSD in our cultures differs from what has been described in Aicardi-Goutiè res syndrome lymphocytes, but this might be attributed either to the lack of Aicardi-Goutiè res syndrome mutations in our cells or differences in tissue specificity. Indeed, a recent study demonstrates that only in TREX1-deficient lymphocytes is a remarkable upregulation of CTSD after IFNexposure observed, in comparison with the moderate increase described in healthy control cells (Pulliero et al., 2012) . Moreover, we found an upregulation of CST7 in astrocytes in the white matter of Aicardi-Goutiè res syndrome brain specimens and demonstrated that ATF4 and eIF2B (a DNAJ downstream transcription and translation factor, respectively) were both downregulated in astrocytes on chronic exposure to IFN-. These findings are remarkable, as mutations in EIF2B subunit genes cause vanishing white matter disease with a severe loss of oligodendrocytes and astrocytes early in life (Pronk et al., 2006; Carter, 2007) . Indeed, defects in EIF2B in vanishing white matter disease lead to an increased unfolded protein response (ATF4 induction) in fibroblasts as a consequence of endoplasmic reticulum stress (Kantor et al., 2005) . Even though more research is needed, eIF2B might be a common factor in the pathogenesis of both leukodystrophies. Having said that, these two pathologies have different disease mechanisms. Although treatment of astrocyte cultures with IFN-dramatically increased the expression of human leukocyte antigens, as was reported previously (Tedeschi et al., 1986) , it is important to emphasize that neither neurons nor oligodendrocytes express human leukocyte antigen molecules when exposed to IFN-in vitro. Our findings agree with those of others (Akwa et al., 1998; Campbell et al., 1999; van Heteren et al., 2008) in pointing to astrocytes as the main players in the autoinflammation of the brain in Aicardi-Goutiè res syndrome.
Our finding that chronic exposure to IFN-reduced the production of pro-angiogenic factors by astrocytes may offer a partial explanation for the cerebrovascular problems reported in patients with Aicardi-Goutiè res syndrome (Barth et al., 1999; Rasmussen et al., 2005; Ramesh et al., 2010) . IFN-is known to reduce angiogenesis and is actually used as adjuvant therapy to treat certain types of cancer (Kirkwood, 2002) . For the first time, we now report IFN-to inhibit the production of VEGF by astrocytes as well as the production of some cytokines, including IL-1 and TNF-. Downregulation of VEGF and IL-1 was confirmed in Aicardi-Goutiè res syndrome brain specimens. The potential importance of this finding lies in the fact that VEGF is expressed exclusively by astrocytes in the adult brain (Yang et al., 2003; Bernal and Peterson, 2011) . We speculate that the impaired availability of these angiogenic factors in the brains of infants might lead to an abnormal vessel formation and proliferation. Indeed, we observed an aberrant vasculature with excessive number of capillary-like blood vessels, especially in cortical areas in the Aicardi-Goutiè res syndrome specimens. Moreover, degeneration of neurons is found in subcortical areas (mammillary bodies, thalamus, striatum and globus pallidus) of Aicardi-Goutiè res syndrome brains (Barth et al., 1999; Rasmussen et al., 2005) . Besides the primary role of VEGF in vascular development, it is also known to induce neurogenesis (Jin et al., 2002) and to be neuroprotective under stress conditions (Falk et al., 2011; Ma et al., 2011) . Although vascular insufficiency might be crucial for the degenerative process, the reduced amount of trophic factors may worsen the neurodegeneration in these cerebral areas.
Cerebral calcifications are one of the most common findings in Aicardi-Goutiè res syndrome (Uggetti et al., 2009) . However, brain calcifications are non-specific and are found in many pathological conditions. Given the anatomical distribution of microcalcifications in the white matter and around blood vessels, we hypothesized that astrocytes were good candidates for the production of calcium deposits. However, we did not find supportive evidence for such. Also, we observed no change in transcriptional activity of SLC20A2 and COL4A1, both genes being related to intracranial calcifications on loss of function mutations (Livingston et al., 2011; Wang et al., 2012) . Similarly, osteopontin has also been described to be involved in brain calcification and localizes in degenerating neurites (Shin et al., 2012) . However, we were not able to detect any osteopontin messenger RNA in our astrocyte cultures. Hence, it remains to be elucidated which cell type is responsible for the cerebral calcifications observed in Aicardi-Goutiè res syndrome.
In summary, we describe a new in vitro model of AicardiGoutiè res syndrome that provides insight into the dysregulated expression of genes and proteins affecting the stability of white matter and the cerebral vasculature in the postnatal manifestations of this brain disease. Noteworthy is the fact that IFN-withdrawal did not produce a clear recovery to pre-treatment gene/protein expression levels in vitro. Instead, the IFN--induced gene expression signature seems to be persistent over time. Several authors have suggested that anti-IFN-therapy might be beneficial in the treatment of Aicardi-Goutiè res syndrome. Based on our data, we postulate that therapeutic targets for Aicardi-Goutiè res syndrome, and other IFN--related encephalopathies, might include downstream IFN-signalling effectors besides IFN-itself, as the effect of IFN-may be long-lasting and cannot always be reversed instantly on simple withdrawal or neutralization.
